Your browser doesn't support javascript.
loading
A multicenter phase II study of bendamustine, rituximab, and cytarabine (BRAC) for relapsed or refractory patients with follicular lymphoma or mantle cell lymphoma.
Nakamura, Nobuhiko; Kasahara, Senji; Kitagawa, Junichi; Nakamura, Hiroshi; Sawada, Michio; Fukuno, Kenji; Shibata, Yuhei; Kaneda, Yuto; Hara, Takeshi; Kanemura, Nobuhiro; Tsurumi, Hisashi; Shimizu, Masahito.
Afiliación
  • Nakamura N; Department of Hematology and Infectious Disease, Gifu University Hospital, 1-1, Yanagido, Gifu, 501-1194, Japan. nnaka@gifu-u.ac.jp.
  • Kasahara S; Department of Hematology, Gifu Municipal Hospital, Gifu, Japan.
  • Kitagawa J; Department of Hematology, Gifu Municipal Hospital, Gifu, Japan.
  • Nakamura H; Department of Hematology and Infectious Disease, Gifu University Hospital, 1-1, Yanagido, Gifu, 501-1194, Japan.
  • Sawada M; Department of Hematology, Gifu Red Cross Hospital, Gifu, Japan.
  • Fukuno K; Department of Hematology, Takayama Red Cross Hospital, Gifu, Japan.
  • Shibata Y; Department of Hematology, Gifu Municipal Hospital, Gifu, Japan.
  • Kaneda Y; Department of Hematology, Takayama Red Cross Hospital, Gifu, Japan.
  • Hara T; Department of Hematology, Matsunami General Hospital, Gifu, Japan.
  • Kanemura N; Department of Hematology and Infectious Disease, Gifu University Hospital, 1-1, Yanagido, Gifu, 501-1194, Japan.
  • Tsurumi H; Department of Hematology and Infectious Disease, Gifu University Hospital, 1-1, Yanagido, Gifu, 501-1194, Japan.
  • Shimizu M; Department of Hematology, Matsunami General Hospital, Gifu, Japan.
Exp Hematol Oncol ; 11(1): 9, 2022 Feb 25.
Article en En | MEDLINE | ID: mdl-35216626
This phase II clinical trial aimed to evaluate the efficacy and safety of the combination therapy of bendamustine, cytarabine, and rituximab (BRAC) in patients with relapsed or refractory follicular lymphoma (FL) or mantle cell lymphoma (MCL). Thirteen patients were enrolled and received a median of 4 cycles (range 2-6) of BRAC. The complete response rate was 61.5%, and the overall response rate was 84.6%; the 2-year overall survival was 76.9%, and the 2-year progression-free survival was 69.2%. Although all patients received G-CSF prophylaxis, grade 3 or higher neutropenia was observed in all cycles, and the incidence of febrile neutropenia was 20%. Grade 4 thrombocytopenia was observed in 92.5% of all cycles, and platelet transfusion was performed in 94%. Although hematological toxicity was relatively high, BRAC therapy was effective for relapsed and refractory FL or MCL. Further studies are needed to determine the optimal dose of BRAC therapy.Trial registration The UMIN Clinical Trials Registry, UMIN000009797. Registered 17 January 2013, https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000011103.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Exp Hematol Oncol Año: 2022 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Exp Hematol Oncol Año: 2022 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Reino Unido